alexa Hepatic safety profile of darunavir with low-dose ritonavir (DRV r) in HIV HCV coinfected and HIV monoinfected patients.
Infectious Diseases

Infectious Diseases

Journal of AIDS & Clinical Research

Author(s): Morsica G, Bianchi G, Bagaglio S, Conte C, Salpietro S, , Morsica G, Bianchi G, Bagaglio S, Conte C, Salpietro S,

Abstract Share this page

Abstract The hepatic safety profile of ART including DRV/r was retrospectively evaluated in antiretroviral-experienced HIV-infected patients (18 HIV/HCV coinfected, group A and 29 infected with HIV alone, group B) during a 72 week study. During the study, liver enzyme values were higher in group A, but in the case of abnormal transaminase levels, the median values did not exceed 1.6xULN. This study showed evidence of long-lasting hepatic safety of ART including PI DRV/r in HIV/HCV coinfected and in HIV monoinfected persons.
This article was published in New Microbiol and referenced in Journal of AIDS & Clinical Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version